{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:05:35Z","timestamp":1778724335228,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.021","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T01:33:02Z","timestamp":1496021582000},"page":"3666-3671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008\u20132013"],"prefix":"10.1016","volume":"35","author":[{"given":"Wendi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Pekka","family":"Nuorti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna M.","family":"Nohynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Disha","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiakai","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.021_b0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7883\/yoken.JJID.2009.331","article-title":"Japanese encephalitis in mainland China","volume":"62","author":"Huanyu","year":"2009","journal-title":"Jpn J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.021_b0010","first-page":"69","article-title":"Japanese Encephalitis vaccines: WHO position paper-February 2015","volume":"90","author":"World Health Organization","year":"2015","journal-title":"WER"},{"key":"10.1016\/j.vaccine.2017.05.021_b0015","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.vaccine.2013.11.107","article-title":"Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Gyangdong, China, 2005\u20132012","volume":"32","author":"Liu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.021_b0020","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/S0264-410X(00)00111-0","article-title":"Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States","volume":"18","author":"Takahashi","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.021_b0025","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.vaccine.2006.05.130","article-title":"Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994\u20132004","volume":"25","author":"Nakayama","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.021_b0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0163-4453(96)91281-5","article-title":"Adverse reactions to Japanese encephalitis vaccine in travelers","volume":"32","author":"Nothdurft","year":"1996","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2017.05.021_b0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.vaccine.2017.05.021_b0040","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/INF.0b013e3181f68e9c","article-title":"Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial","volume":"29","author":"Chokephaibulkit","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.021_b0045","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1086\/517323","article-title":"Short-term safety of live attenuated Japanese encephalitis vaccine (SA1414-2): results of a randomized trial with 26,239 subjects","volume":"176","author":"Liu","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.021_b0050","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.vaccine.2015.04.060","article-title":"Surveillance of adverse events following immunization in China: past, present, and future","volume":"33","author":"Dawei","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.021_b0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa1008553","article-title":"Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China","volume":"364","author":"Xiaofeng","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.05.021_b0060","series-title":"National guideline for the surveillance of adverse events following immunization","author":"China Ministry of Health Food and Drug Administration of China","year":"2010"},{"key":"10.1016\/j.vaccine.2017.05.021_b0065","series-title":"Chinese standard procedures for vaccination","author":"China Ministry of Health","year":"2005"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.021_b0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining \u2018Signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions","volume":"32","author":"Hauben","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2017.05.021_b0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRR) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2017.05.021_b0080","unstructured":"European Medicines Agency. Eudra Vigilance Expert Working Group. Guideline on the use of statistical signal detection methods in the Eudra Vigilance data analysis system [EMEA\/106464\/2006 rev. 1] [Online] Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011434.pdf [accessed 2015.8.11]"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.021_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","article-title":"A data mining approach for signal detection and analysis","volume":"25","author":"Bate","year":"2002","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2017.05.021_b0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (with discussion)","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.021_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00002018-200629050-00002","article-title":"Data mining in the US using the vaccine adverse event reporting system","volume":"29","author":"Iskander","year":"2006","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.vaccine.2017.05.021_b0100","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.05.021_b0105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/pharmaceutics4040607","article-title":"Signal detection and monitoring based on longitudinal healthcare data","volume":"4","author":"Suling","year":"2012","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.021_b0110","first-page":"385","article-title":"Analysis on surveillance data of adverse events following immunization in China, 2010","volume":"18","author":"Wu","year":"2012","journal-title":"Chin J Vacc Immuniz"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.021_b0115","first-page":"97","article-title":"Analysis on surveillance data of adverse events following immunization in China, 2011","volume":"19","author":"Wu","year":"2013","journal-title":"Chin J Vacc Immuniz"},{"issue":"1","key":"10.1016\/j.vaccine.2017.05.021_b0120","first-page":"1","article-title":"Analysis on surveillance data of adverse events following immunization in China, 2012","volume":"20","author":"Wu","year":"2014","journal-title":"Chin J Vacc Immuniz"},{"issue":"29","key":"10.1016\/j.vaccine.2017.05.021_b0125","first-page":"301","article-title":"Global advisory committee on vaccine safety, 12\u201313 June 2013","volume":"88","author":"GACVS\/WHO","year":"2013","journal-title":"WER"},{"key":"10.1016\/j.vaccine.2017.05.021_b0130","unstructured":"WHO. Available from URL: http:\/\/www.who.int\/immunization_standards\/vaccine_regulation\/nra_china_functional\/en\/accessed [15.9.2015]"},{"key":"10.1016\/j.vaccine.2017.05.021_b0135","unstructured":"WHO. Available from URL: http:\/\/www.who.int\/mediacentre\/news\/releases\/2013\/japanese_encephalitis_20131009\/en\/ [accessed 14.9.2015]"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.021_b0140","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.021_b0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/pds.1323","article-title":"Data mining for signals in spontaneousreporting databases: proceed with caution","volume":"16","author":"Stephenson","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2017.05.021_b0150","first-page":"9","article-title":"Febrile convulsion: review and update","volume":"2","author":"Daoud","year":"2004","journal-title":"J Pediat Neurol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.021_b0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7150\/ijms.4.110","article-title":"Childhood febrile seizures: overview and implications","volume":"4","author":"Jones","year":"2007","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.vaccine.2017.05.021_b0160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/adc.2003.028449","article-title":"Febrile seizures: an update","volume":"89","author":"Waruiru","year":"2004","journal-title":"Arch Dis Child"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2017.05.021_b0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1528-1167.2011.03032.x","article-title":"Vaccinations and febrile seizures","volume":"52","author":"Cendes","year":"2011","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.vaccine.2017.05.021_b0170","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jama.2012.165","article-title":"Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b","volume":"307","author":"Sun","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.05.021_b0175","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile seizures after 2010\u20132011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system","volume":"30","author":"Leroya","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.021_b0180","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsena","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.021_b0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the vaccine adverse event reporting system","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.021_b0190","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1086\/517323","article-title":"Short-Term safety for live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26239 subjects","volume":"176","author":"Zheng-Le","year":"1997","journal-title":"JID"},{"key":"10.1016\/j.vaccine.2017.05.021_b0195","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T11:23:59Z","timestamp":1719228239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":39,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17306291"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008\u20132013","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}